Elza Lomaia

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Andreas Hochhaus, Delphine Réa, Carla Boquimpani et al. · Leukemia · 2023 · 126 citations · Full text

Mixed-phenotype Acute Leukemia, Asciminib Vs Bosutinib, Pharmacotherapy +17

First‐line treatment selection and early monitoring patterns in chronic phase‐chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Stuart L. Goldberg, Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. · American Journal of Hematology · 2017 · 39 citations · Full text

Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

Vikas Gupta, Martin Grießhammer, Bruno Martino et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 33 citations · Full text

Prognosis, Pathology, Pharmacotherapy +16

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Michael Lauseker, Katharina Bachl, Anna Turkina et al. · American Journal of Hematology · 2019 · 28 citations · Full text

Hematological Malignancy, Chronic Myeloid Leukemia, Health Sciences +15

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, Carla Boquimpani, Delphine Réa et al. · Blood · 2020 · 26 citations